WO2001009154A2 - UTILISATION DE LA STRUCTURE CRISTALLINE DE LA SYNTHETASE ARNt-ISOLEUCYLE DU STAPHYLOCOCCUS AUREUS DANS LA CONCEPTION D'ANTIBIOTIQUES - Google Patents

UTILISATION DE LA STRUCTURE CRISTALLINE DE LA SYNTHETASE ARNt-ISOLEUCYLE DU STAPHYLOCOCCUS AUREUS DANS LA CONCEPTION D'ANTIBIOTIQUES Download PDF

Info

Publication number
WO2001009154A2
WO2001009154A2 PCT/US2000/020735 US0020735W WO0109154A2 WO 2001009154 A2 WO2001009154 A2 WO 2001009154A2 US 0020735 W US0020735 W US 0020735W WO 0109154 A2 WO0109154 A2 WO 0109154A2
Authority
WO
WIPO (PCT)
Prior art keywords
irs
trna
crystal
agent
mupirocin
Prior art date
Application number
PCT/US2000/020735
Other languages
English (en)
Other versions
WO2001009154A3 (fr
Inventor
Jimin Wang
Laura F. Silvian
Thomas A. Steitz
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Priority to AU63915/00A priority Critical patent/AU6391500A/en
Priority to CA002380335A priority patent/CA2380335A1/fr
Priority to EP00950881A priority patent/EP1200564A2/fr
Publication of WO2001009154A2 publication Critical patent/WO2001009154A2/fr
Publication of WO2001009154A3 publication Critical patent/WO2001009154A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93—Ligases (6)

Definitions

  • TITLE Use of the Crystal Structure of Staphylococcus Aureus Isoleucyl- tRNA Synthetase in Antibiotic Design
  • the present invention arose in part from research funded by National Institute of Health grant GM-22778.
  • the present invention relates to the crystalline structure of isoleucyl-tRNA synthetase and the cognate tRNA lle and to methods of producing such crystals.
  • the invention also relates to the atomic coordinates of isoleucyl-tRNA synthetase and the cognate tRNA lle , obtained by x-ray diffraction at high resolution.
  • the present invention also relates to methods for identifying and designing new classes of ligands which target the isoleucyl-tRNA synthetases of specific organisms.
  • the methods and compositions of the present invention find wide applicability in the design and production of antibiotics, insecticides, miticides and herbicides.
  • Mupirocin is the active ingredient of BactrobanTM, a trademark of SmithKline Beecham. All attempts so far have failed to modify this antibiotic with either improved stability against unknown human hydrolase(s) for in vivo use or improved selectivity for its pathogenic target enzyme over human enzyme, simply because no organic chemists know how to modify the antibiotic to achieve the above goals.
  • Staphylococcus aureus present in about two-thirds of healthy individuals in the entire population, has a long association with nosocomial infection and is a virulent pathogen that is currently the most common cause of infections in hospitalized patients (Archer, 1998, Gould and Chamberlaine, 1995).
  • SA Staphylococcus aureus
  • methicillin-resistant S. aureus became a severe problem in the 1980s (Vandenbrouche-Grauls, 1994, Mulligan et al., 1993), and is resistant to all ⁇ -lactams because it produces a new penicillin binding protein to remove all related antibiotic, pencillins, cephalosporins, carbapenems, and penems (Lyon and Skurray, 1987; Ubukata et al., 1985; Murakami and Tomasz, 1989; Tesch et al, 1988; Chambers and Sachdeva, 1990).
  • vanomycin the only effective antibiotic and often reserved for use in patients who are gravely ill. Its increased use has created vancomycin-resistant pathogens including S. aureus (Flores and Gordon, 1997, Perl, 1999, Paterson, 1999, Neu, 1992).
  • Mupirocin a derivative of pseudomonic acid from Pseudomona fluorescens (Fuller et al, 1971), is highly effective against MRSA (Bertino, 1997, Dacre et al, 1986). Differing from cell wall-inhibiting antibiotic, it binds isoleucyl-tRNA synthetase (IRS) as a competitive inhibitor for isoleucine and inhibits protein biosynthesis (Hughes and Mellows, 1978ab; Hughes and Mellows, 1980; Yanagisawa et al, 1994; Pope et al, 1998ab).
  • IFS isoleucyl-tRNA synthetase
  • Topical use of mupirocin has very successfully eradicated the nasal carriage of MRSA (Harbarth et al, 1999; Redhead et al, 1991; Casewell and Hill, 1989; Caderna et al, 1990). This is extremely important because the anterior opening to the nasal cavities (i.e., the naris or nares), are the major site where MRSA and susceptible staphylococci persist. Topical use also eradicated MRSA in skin and virginal infections after the failure of intervenous vancomycin therapy (Denning and Haiduven-Griffiths, 1988, Cool-Foley et al, 1991). Despite these success, a person could still die in a hospital in any major city with a resistant bacterial infection.
  • MURSA mupirocin resistant S. aureus
  • Mupirocin is not very effective against bacteremia caused by MRSA because of its short half-life metabolic conversion in vivo from pseudomonic acid to inactive monic acid, which is rapidly cleared in the urine (Mellows, 1989).
  • the pharmaceutical industry has been unsuccessful in slowing or halting the enzymatic hydrolysis by modifying the structure and function of the C1-C3 fragment, although the modified antibiotic retains good in vitro activity (Rogers 1980, Rogers and Coulton, 1882, Banks et al, 1989).
  • This fragment has also been replaced by an unsaturated 5-membered heterocycle ring, but it must retain low-energy unoccupied molecular orbital for its inhibitory activity (Brown et al, 1997). Selectivity of Isoleucyl-tRNA Synthetase
  • Isoleucyl-tRNA synthetase selectively adds isoleucine to isoleucyl- tRNA, while rejecting all other amino acids and all other noncognate tRNAs.
  • This enzymatic selectivity of isoleucine over valine is over 3000-fold (Loftfield, 1 63; Loftfiled and Vanderjagt, 1972). If IRS were an inorganic catalyst, a free energy difference of one single methylene group between the two amino acids would provide only about 5-fold difference in selectivity (Pauling, 1958) based on an adsorption theory, which has successfully explained catalytic mechanisms for nearly all inorganic catalysts.
  • inorganic catalysts such as transition metal ions accelerate rates of chemical reactions by increasing the collision frequency through adsorbing two reactants on catalysts' surface.
  • the rate of enhancement is a function of adsorption of free energy
  • the selectivity of given reactions is a function of free energy differences in the adsorption.
  • IRS Hydrolysis by IRS includes two substrates, both of which are the IRS synthetic products.
  • One is an incorrectly acylated valine-tRNA 1,e , also known as a post-transfer product, and the other, the dominant substrate for hydrolysis, is an activated noncognate valine-adenylate, also known as a pre-transfer product (Fersht, 1977).
  • IRS is a model system for mechanistic studies of editing tRNA synthetases (Freist, 1989). Nureki et al. recently (1998) determined the IRS crystal structure from T. thermophilus (Tth) and showed that indeed there are two active sites, located in two distinct domains, separated by over 34 A, providing direct evidence for the double-sieve hypothesis.
  • Nureki et al. discloses the crystal structure of T. thermophilus IRS complexed to L-isoleucine or L-valine.
  • the crystal structure has a resolution of 2.4 A and is obtained by analysis of X-ray crystallographic diffraction data of the crystal.
  • the crystal of Nureki et al (1998) show that the first step in substrate selection is on the aminoacylation domain containing the Rossmann fold, whereas the second step, the editing step, exists on a globular ⁇ -barrel domain that protrudes from the amino acylation domain.
  • thermophilus are homologous, and the active sites of these synthetases are also structurally similar.
  • the crystal structure of Nureki et al. (1998) does not include structural information for mupirocin or tRNA lle and how mupirocin, other protein synthesis inhibitors, or tRNA lle interacts with T. thermophilus IRS.
  • the present invention discloses the crystal structure of S. aureus IRS complexed to muciprocin and tRNA 1,e .
  • the present invention shows how IRS interacts with an inhibitor of protein synthesis, in the presence of tRNA lle .
  • the present invention provides methods of preparing crystals of a complex comprising isoleucyl-tRNA synthetase (IRS) complexed with mupirocin, and tRNA lle which includes mixing IRS, mupirocin, and tRNA lle with a well solution to form a mixture; streak-seeding drops of the mixture; vapor equilibrating the seeded drops in a closed container against the well solution to obtain a crystal of the complex and to produce an equilibrated crystal drop solution; replacing the equilibrated crystal drop solution with a cryoprotectant; and flash- freezing the crystal.
  • IRS isoleucyl-tRNA synthetase
  • the present inventions provides such methods wherein the well solution comprises about 12% PEG 6K, about 0.3 M KC1, about 100 mM Na Cacodylate pH 6.3, about 100 mM MgSO 4 , about 2 mM ZnCl 2 and about 0.1 % ⁇ -octyl glutopyranoside.
  • the present invention also provides such methods wherein the seeded drops are equilibrated by hanging drop method.
  • the present invention further provides such methods wherein the cryoprotectant comprises about 20% PEG 6K, about 0.3M KC1, about lOOmM Na Cacodylate pH 6.3, about lOOmM MgSO 4 , about 2mM ZnCl 2 about 0.1% ⁇ -octyl glutopyranoside, and about 15% ethylene glycol.
  • the present invention also provides such methods wherein the crystal is flash-frozen in liquid propane.
  • the present invention also provides crystals of IRS, mupirocin and tRNA lle . More particularly, the present invention provides such crystals wherein the crystals effectively diffract X-rays for determination of atomic coordinates of the complex to a resolution of about 2.2 A.
  • the present invention provides such crystals wherein the crystals belong to the space group
  • the present invention provides crystals which have an atomic structure characterized by the coordinates deposited at the Protein Data bank with accession number PDB ID: IFFY.
  • the present invention provides the above-listed crystals which are obtained from Staphylococcus aureus.
  • the present invention also provides methods for identifying agents (ligands) that interact with IRS and tRNA' le , wherein such methods include obtaining a crystal of a complex comprising IRS, tRNA lle and mupirocin; obtaining the atomic coordinates of the crystal; and using the atomic coordinates and one or more molecular modeling techniques to identify an agent that interacts with IRS and tRNA ile .
  • the present invention further provides methods of identifying agents (ligands) that interact with IRS wherein such methods include obtaining a crystal of a complex comprising IRS, tRNA lle and mupirocin; obtaining the atomic coordinates of the crystal; and using the atomic coordinates and one or more molecular modeling techniques to identify an agent that interacts with IRS.
  • the present invention provides such methods of identifying agents (ligands) wherein the one or more molecular modeling techniques include graphic molecular modeling and computational chemistry.
  • the present invention further provides such methods of identifying agents (ligands) and then contacting the agents with IRS and detecting the amount and degree of binding of the agents to IRS.
  • the methods of the present invention can be used to identify agents that bind to enzymes from the same or different species as the species from which the enzyme was obtained to produce the crystal.
  • the present invention further provides such methods of identifying agents which include altering the identified agents and contacting the altered agents with IRS and determining the binding of the altered agents to IRS.
  • the present invention also provides altered agents produced by such methods wherein the altered agents bind differently to IRS than do the agents from which the altered agents were derived.
  • the present invention further provides such altered agents wherein the altered agents are therapeutic agents. More particularly, the present invention provides such altered agents wherein the altered agents have desirable pharmaceutical properties.
  • the invention further provides compositions which include such altered agents combined with pharmaceutically-acceptable carriers. More particularly, the present invention provides altered agents which act as inhibitors of IRS.
  • the agents of the present invention can be specifically designed to kill or act as inhibitors of target organisms while not killing non-target organisms or inhibiting non-target organisms less at the same concentration of the altered agents.
  • the present invention also provides methods of identifying inhibitors of protein synthesis which include obtaining crystals of a complex comprising IRS, tRNA' 1e and mupirocin; obtaining the atomic coordinates of the crystals; using the atomic coordinates and molecular modeling techniques to identify agents that interact with IRS; assaying the inhibitory properties of the agents by administering them to cells, cell extracts or purified IRS; and detecting protein synthesis, wherein a decrease in protein synthesis indicates that the agents are inhibitors of protein synthesis.
  • the present invention also provides such methods wherein assaying the inhibitory properties of the agents includes detecting protein synthesis and wherein a decrease in protein synthesis indicates that the agents are inhibitors of protein synthesis.
  • assaying the inhibitory properties of the agents includes determining an inhibition constant for inhibiting isoleucyl-tRNA synthesis reaction by the agents.
  • the present invention also provides methods of identifying inhibitors of protein synthesis which include obtaining crystals of a complex comprising IRS, fRNA ,,e and mupirocin; obtaining the atomic coordinates of the crystals; using the atomic coordinates and molecular modeling techniques to identify agents that interact with IRS; and assaying the inhibitory properties of the agents by administering them to cells, a cell extracts or purified IRS to determine whether they are inhibitors of protein synthesis.
  • the present invention also provides such methods wherein assaying the inhibitory properties of the agents includes determining whether the agents inhibit isoleucyl- tRNA synthesis. More particularly, the present invention provides such methods wherein whether the agents inhibit isoleucyl-tRNA synthesis are determined by measuring the generation of pyrophosphate or the formation of isoleucyl- tRNA ile .
  • Dashed arrows represent hydrogen bonds between the antibiotic and the enzyme.
  • the dashed arcs indicate important hydrophobic interactions.
  • Part A also known as the head of the antibiotic, is the portion of the molecule that corresponds to carbons 9-14 of mupirocin.
  • Part B also known as the central portion, is the portion of the molecule that mimics the adenosine-ring portion of the adenylate.
  • HIGH and KMSM are the two conserved sequence motifs. Filled triangles represent stereoisomers with the bonds pointing to the viewer; opened triangles represent stereoisomers with the bonds pointing away from the viewers.
  • Amino acids of the enzyme represent defined elsewhere herein.
  • the mupirocin binding site comprises residues P56, P57, H64, G66, N70, E554, G555, D557, Q558, W562, H585, G586, F587, V588, M596, and S597. Amino acids of the enzyme are defined elsewhere herein.
  • FIG. 1 A Comparison of the Binding of Mupirocin or MPC (cyan) and Glutaminyl Sulfomyl Adenylate Inhibitor or QSI.
  • WSS-1 is designed from the antibiotic, mupirocin, in three steps:
  • FIG. 1 A Binding Model of WSS-1 to MURSA IRS.
  • WSS-1 (cyan) is bound to MURSA in the identical way as mupirocin (not shown) to SA IRS.
  • SA side chains that different from MURSA are in magenta. The numbering is according to SA IRS.
  • Amino acids of the enzyme are defined elsewhere herein.
  • Figure 6. A List of Atomic Coordinates of WSS-1, Human IRS, and Mupirocin- Resistant Staphylococcus Aureus IRS that are Different from the Atomic Coordinates Corresponding to Staphylococcus Aureus IRS Deposited RCSB Protein Data Bank with the Accession Number PDB ID: IFFY.
  • FIGS. 7A-C An Overview of Editing tRNA Synthetases.
  • the seven synthetase domains are: amino terminal (in brown), dinucleotide Rossmann fold (in green), editing in (golden), CP2 (in blue), helical (in magenta), C- terminal junction (in cyan), and Zn-binding (in red).
  • RNA binding, synthetic (blue circles), and hydrolytic (red circles) active sites are indicated.
  • Figure 8 A Stereodiagram of the RNA Duplex-Pairs of Synthetase ⁇ -Helices Interactions at the Acceptor Stem. Arrows indicate chain directions for tRNA and synthetase.
  • FIGS 9A-E The KMSK Loop Switching and tRNA-RS Interactions.
  • A tRNA-IRS interactions.
  • B tRNA-QRS interactions.
  • C A stereodiagram of (A) and (B).
  • D An additional domain on the top of the KMSK loop in non-editing tRNA synthetase, QRS.
  • FIGS 11A-C A tRNA lle releasing pathway suggests that it must first go through the error-proof checking step in the hydrolytic mode.
  • C-terminal junction domain blocks the horizontal left exit; the CPl domain blocks the up exit and an exit towards the viewer. The CPl domain must rotate before the tRNA can be released.
  • tRNA lle can be released from IRS in the hydrolytic mode in two indicated exits.
  • FIGS 13A-B An extension to the domain-swapping theory.
  • CP-1 Connective peptide 1 inserted into the Rossmann fold domain
  • CP-2 Connective peptides 2 inserted into the Rossmann fold domain
  • HOH solvent molecules
  • IRS Isoleucyl-tRNA synthetase
  • LRS Leucinyl-tRNA synthetase
  • MMI, MM2, MM3, MM4, MM5, MM6, MM7 metal ion complexes (Metal ions are indicated by "#" as in MMI .)
  • MRS Methionyl tRNA synthetase
  • MRSA Methiciline resistant Staphylococcus aureus
  • MURSA Mupirocin resistant Staphylococcus aureus
  • Psefl Pseudomonic ⁇ uoscenes
  • QRS Glutaminyl tRNA-synthetase
  • QSI Glutaminyl sulfomyl adenylate analogous inhibitor
  • Tth Thermus Thermophilus.
  • VRS Valinyl tRNA-synthetase
  • Uri Uridine tRNA residues are in three-letters as in Gua68.
  • atomic coordinates or “structure coordinates” refers to mathematical coordinates derived from mathematical equations related to the patterns obtained on diffraction of a monochromatic beam of x-rays by the atoms
  • RCSB Structural Bioinformatics
  • atomic coordinate refers to the measured position of an atom in the structure in Protein Data Bank (PDB) format, including X, Y, Z and B, for each of the atoms in the amino acids and nucleotides, and in mupirocin.
  • the assembly of “atomic coordinate” also refers to "atomic coordinates” or "structure coordinates”.
  • atom type refers to the element whose coordinates are measured. The first letter in the column defines the element.
  • X,Y,Z refers to the crystallographically defined atomic position of the element measured with respect to the chosen crystallographic origin.
  • B refers to a thermal factor that measures the mean displacement of the atom around its atomic center.
  • Amino acids of the enzyme, nucleotides of the tRNA, and the antibiotic, mupirocin, solvent molecules, and metal ion complexes are defined elsewhere herein.
  • crystal refers to any three-dimensional ordered array of molecules that diffracts X-rays to give spots.
  • complex refers to the assembly of two or more molecules to yield a higher order structure as with IRS bound to tRNA' le and mupirocin.
  • composition refers to the combining of distinct elements or ingredients to form a whole.
  • a composition comprises more than one element or ingredient.
  • a composition will often, but not always, comprise a carrier.
  • the term "crystallographic origin” refers to a reference point in the unit cell with respect to the crystallographic symmetry operation.
  • the term “unit cell” refers to a basic parallelepiped shaped block. The entire volume of crystal may be constructed by regular assembly of such blocks. Each unit cell comprises a complete representation of the unit of pattern, the repetition of which builds up the crystal.
  • the term “isoleucyl-tRNA synthetase (IRS)” refers to an enzyme that very specifically attaches the amino acid isoleucine to the 3' end of the t- RNA molecules that code for tRNA, tRNA i,e .
  • space group refers to the arrangement of symmetry elements of a crystal.
  • symmetry operation refers to an operation in the given space group to place the same atom in one asymmetric unit cell to another.
  • asymmetric unit refers to a minimal set of atomic coordinates that can be used to generate the entire repetition in a crystal.
  • the term "heavy atom derivatization” refers to the method of producing a chemically modified form, also know as “heavy atom derivatives", of crystal of the said enzyme complex.
  • a crystal is soaked in a solution containing heavy atom metal atom salts or organometallic compounds, e.g., mercury chlorides, ethyl-mercury phosphate, which can diffuse through the crystal and bind to the either tRNA or the synthetase.
  • the location(s) of the bound heavy metal atom(s) can be determined by x-ray diffraction analysis of the soaked crystal. This information, in turn, is used to generate the phase information used to construct three- dimensional structure of the complex (Blundel, T.L., and Johnson, N.L., Protein crystallography, Academic Press, 1976).
  • molecular modeling refers to the use of computers to draw realistic models of what molecules look like.
  • the methods used in molecular modeling range from molecular graphics to computational chemistry.
  • molecular model refers to the three dimensional arrangement of the atoms of a molecule connected by covalent bonds.
  • molecular graphics refers to 3D representations of the molecules.
  • computational chemistry refers to calculations of the physical and chemical properties of the molecules.
  • MIR refers to multiple isomorphous replacement, which heavy atom derivatives are prepared.
  • MAD refers to multiple-wavelength anomalous dispersion method, which x-ray diffraction experiments are carried out using the tunable x-ray sources at several wavelengths. This can be used for data collection for heavy atom derivatized crystals or selenomethionine incorporated IRS crystals. This method can be used to generate the phase information. Selenomethionine may be incorporated into wide-type or mutant IRS by expression of IRS-encoding cDNAs in autrophic E. coli strains. Hendrickson, W.A.
  • Selenomethionine may also be incorporated into IRS by shutting down biosynthesis of methionine using externally supplied leucine, isoleucine and selenomethionine to the growth medium at the time of the overexpressing the IRS enzyme.
  • the term "molecular replacement” refers to a method that involves generating a preliminary model of an IRS crystal whose coordinates are unknown, by orienting and positioning the said atomic coordinates described in the present invention so as best to account for the observed diffraction pattern of the unknown crystal. Phases can then be calculated from this model and combined with the observed amplitudes to give an approximate Fourier synthesis of the structure whose coordinates are unknown. (Rossmann, M.G., ed., "The Molecular Replaceir ent Method", Gordor. t Breach, New York, 1972).
  • the term "homologue” refers to the said enzyme, IRS, from one source having at least 25% amino acid identity with the said enzyme or any functional domain of the said enzyme from another source.
  • Staphylococcus aureus IRS and human IRS are homologues because they share 26% identity
  • Staphylococcus aureus IRS and mupirocin-resistant Staphylococcus aureus IRS are homologues because they share 30% identity.
  • active site refers to either the hydrolytic or the synthetic active sites in the said enzyme.
  • the term "antibiotic binding site” refers to either active site or the mupirocin binding site.
  • the term “mupirocin binding site” or “mupirocin binding cleft” refers to a binding site on IRS comprising amino acid residues adjacent to the bound mupirocin in the structure.
  • the mupirocin binding site comprises of residues P56, P57, H64, G66, N70, E554, G555, D557, Q558, W562, H585, G586, F587, V588, M596, and S597.
  • the term “naturally occurring amino acids” refers to the L- isomers of the naturally occurring amino acids.
  • the naturally occurring amino acids are glycine, alanine, valine, leucine, isoleucine, serine, methionine, threonine, phenylalanine, tyrosine, tryptophan, cysteine, proline, histidine, aspartic acid, asparagine, glutamtic acid, glutamine, ⁇ -carboxylglutamic acid, arginine, ornithine, and lysine. Unless specifically indicated, all amino acids are referred to in this application are in the L-form.
  • unnatural amino acids refers to amino acids that are not naturally found in proteins. For example, selenomethionine.
  • positively charged amino acid includes any amino acids having a positively charged side chain under normal physiological conditions.
  • positively charged naturally occurring amino acids are arginine, lysine, and histidine.
  • negatively charged amino acid includes any amino acids having a negatively charged side chains under normal physiological conditions.
  • negatively charged naturally occurring amino acids are aspartic acid and glutamic acid.
  • hydrophobic amino acid includes any amino acids having an uncharged, nonpolar side chain that is relatively insoluble in water.
  • naturally occurring hydrophobic amino acids are alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine.
  • hydrophilic amino acid refers to any amino acids having an uncharged, polar side chain that is relatively soluble in water. Examples of naturally occurring hydrophilic amino acids are serine, threonine, tyrosine, asparagine, glutamine and cysteine.
  • hydrophilic amino acid refers to two hydrophilic atoms
  • hydrophobic interaction refers to interactions made by two hydrophobic residues or atoms (such as C).
  • aromatic residue refers to amino acids whose side chains have a delocalized conjugated system. Examples of aromatic residues are phenylalanine, tryptophan, and tyrosine.
  • the term "mutant" refers to an IRS polypeptide having at least one amino acid from the wild-type.
  • Such a mutant may be prepared, for example, by expression of IRS cDNA previously altered in its coding sequence by oligonucleotide-directed mutagenesis.
  • Such a mutant may also be generated by site- directed incorporation of unnatural amino acids using the general biosynthetic method of Noren, C.J., et al, Science, 244, pp 182-188 (1989).
  • the codon encoding the amino acid of interest in wild-type IRS is replaced by "blank" nonsense codon, TAG, using oligonucleotide-directed mutagenesis.
  • a suppressor tRNA directed against this codon is then added to an in vitro translation system to yield a mutant IRS enzyme with site-specific incorporated unnatural amino acid.
  • kinetic form of IRS refers to the condition of the enzyme in its free or unbound form or bound to a chemical entity at either hydrolytic or synthetic active sites.
  • the term “competitive inhibitor” refers to inhibitors by binding to the same kinetic form of IRS as its substrate(s) bind, thus directly competing with the substrate(s) for active site(s) of JJ S. Competitive inhibition can be reversed completely by increasing the substrate concentration.
  • the term “uncompetitve inhibitor” refers to one that inhibits
  • IRS by binding to a different kinetic form of the enzyme than does the substrate.
  • Such inhibitors bind to IRS with substrate and not to the free enzyme. Uncompetitive inhibition cannot be reversed completely by increasing the substrate concentration.
  • non-competitive inhibitor refers to one that that can bind to either the free or substrate bound form of IRS.
  • inhibitors may be identified as competitive, uncompetitive, or non-competitive by computer fitting enzyme kinetic data using standard equation according to Segel, I.H., Enzyme Kinetics, J. Willey & Sons, (1975). It should also be understood that uncompetitive or non-competitive inhibitors according to the present invention might bind the same or different binding site of mupirocin.
  • R or S-isomer refers to two possible stereroisomers of a chiral carbon according to the Cahn-Ingold-Prelog system adopted by International Union of Pure and Applied Chemistry (IUPAC).
  • IUPAC International Union of Pure and Applied Chemistry
  • Each group attached to the chiral carbon is first assigned to a preference or priority a, b, c, or d on the basis of the atomic number of the atom that is directly attached to the chiral carbon.
  • the group with the highest atomic number is given the highest preference a, the group with next highest atomic number is given the next highest preference b; and so on.
  • the group with the lowest preference (d) is then directed aways from the viewer.
  • the present invention is based in part on the successful preparation of a crystal for the ternary complex comprising IRS/tRNA lIe /mupirocin, wherein the crystal diffracts X-ray for the determination of atomic coordinates to a resolution of 2.2 A.
  • the present invention provides crystals of the ternary complex and compositions
  • RECTIFIED SHEET (RULE 91) ISA/EP comprising the crystals of the ternary complex.
  • the present invention is based in part on the finding that the crystal comprises an atomic structure characterized by the coordinates deposited on July 26, 2000, at the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB) (Berman et al, 2000, Nucleic Acids Research, 28, 235-242; ttp : //www, rcsb .org/pdb/) with the accession number PDB ID: IFFY.
  • RCSB Structural Bioinformatics
  • PDB Protein Data Bank
  • the present invention is also based in part on the use of the atomic coordinates of the crystal of the IRS/tRNA lle /mupirocin complex to obtain a novel compound WSS-1.
  • the present invention provides the structure of the compound (fig. 4) and provides compositions comprising the compound. 1. The Structure and Stereochemistry of Mupirocin in the Cocrystal Structure
  • mupirocin was built according to experimental electron density maps in an incorrect stereochemistry (Silvian et al, 1999).
  • SA simulated- annealing
  • mupirocin in the cocrystal has the same stereochemistry (or stereoisomer) as mupirocin by itself (Chain et al, 1977, Alexander et al, 1978).
  • the misinterpretation of the mupirocin structure in the early stage was due to the poor quality of electron density maps.
  • the SA-omitted map also clearly shows that (1) the definition of the C2-C3 fragment separated from a stacking phenylalanine side chain and (2) the location of Ol'A and Ol'B (Fig. 1). Both of these features are not present in the original experimental maps.
  • the present invention provides the correct atomic structure for the crystal of the IRS/tRNAile mupirocin complex.
  • the atomic coordinates of the crystal structure are deposited on July 26, 2000 at the RCSB Protein Data Bank with the accession number PDB ID: IFFY.
  • this portion of the antibiotic resembles the ribose of ATP or ATP analogue.
  • Ol 0 interacts with a backbone amine (P57) and a backbone carbonyl (P56) (Fig. 2); and O13, however, is fully exposed.
  • P57 backbone amine
  • P56 backbone carbonyl
  • O13 is fully exposed.
  • 013, inserted at a position equivalent to the isoleucine side chain C ⁇ 1 does not contribute to the binding of the antibiotic through any hydrogen bonds. Removal of this oxygen from mupirocin should not affect its affinity to IRS.
  • this group may serve as a linker for more complex antibiotic design as described below.
  • one of two completely equivalent hydroxyls is hydrogen bonded to the backbone of the KMSKS loop.
  • OIB of the carbonyl of the monic acid part in mupirocin receives a hydrogen from the V388 backbone amide for a hydrogen bond.
  • the functional group of OIB in this antibiotic occupies precisely where Nl of the ATP's adenosine ring. This strictly requires a hydrogen acceptor at this position, which is also known as low-energy unoccupied molecular orbital defined by synthetic and theoretical chemists (Brown et al, 1997). Ol A in
  • the conjugate system (of O1A, OIB, Cl to C4 and C15), C14 and C17 (of isoleucine side chain equivalent), and the part of C5' through C8', as judged by ray lengths of the occluded surface (Wang et al., 1999a).
  • the conjugate system is packed between F587 and H64 of the helix of the HIGH motif.
  • the packing cleft of the branching methyl group C17 is made of the side chain carbon atoms of E554 and Q558 (Fig.2), and the packing cleft of C14 is made of the P56 ring (Fig. 2) and a portion of the W562 side chain.
  • the configuration of Cl 1 is made of the side chain carbon atoms of E554 and Q558 (Fig.2), and the packing cleft of C14 is made of the P56 ring (Fig. 2) and a portion of the W562 side chain.
  • C12 (C ⁇ ), C13 (C ⁇ l), C14 (C ⁇ l), and C17 (C ⁇ 2) is equivalent to the third most populated rotamer conformation in the database (Ponder and Richards, 1987). It is possible that the presence of O13 in the antibiotic may stabilize this rotamer conformation over others.
  • the long hydrophobic tail of the antibiotic mupirocin is essential for its function.
  • the tail is locked into the position in a hydrogen bond with the KMSK backbone (Fig.2), and its C5* through C8' become tightly fitted into the cleft (Wang et al, 1999a).
  • the cleft comprises the side chains of H64 (Fig. 2), M65, and M596 (not shown).
  • the monic acid portion of the antibiotic extends over 14 A, and the hydrophobic tail extends over 10 A with the entire antibiotic over 20 A.
  • monic acid behaves like valine-adenylate and will be constantly shuttled out by the KMSKS loop in an attempt to be hydrolyzed by IRS. This is how the metabolic degradation of mupirocin leads the inactivation of the antibiotic when it is converted to monic acid (Mellows, 1989).
  • the long tail of the fatty acid may also be an advantage for the antibiotic in membrane permeability.
  • the cocrystal structure shows that near the antibiotic binding cleft, there are at least four
  • Mupirocin is an Isoleucine Adenylate Analogue
  • the monic acid portion of mupirocin is a nonhydrolyzable isoleucine adenylate analogue inhibitor (Fig 3).
  • the central portion has four functional oxygen groups, 06, 07, 05 and OIB. They are all recognized by IRS. Similar functional groups are also recognized in nonhydrolyzable glutamine adenylate analogous inhibitor (QSI) by glutaminyl-tRNA synthetase, QRS (Rath et al, 1998).
  • QSI nonhydrolyzable glutamine adenylate analogous inhibitor
  • Nl of QSI receiving a hydrogen from the L261 backbone amide in QRS is equivalent to OIB of mupirocin receiving a hydrogen from the N388 backbone amide in IRS;
  • a hydrogen between H43 in QRS and 04 of QSI is equivalent to one between H64 in IRS and O5 of mupirocin;
  • a hydrogen bond between T230 in QRS and O2 of QSI is equivalent to one between ⁇ 70 in IRS and 06 of mupirocin;
  • (4) a hydrogen bond between its own glutamine and 03' of QSI is equivalent to one between D557 in IRS and 07 of mupirocin in IRS.
  • RECTIFIED SHEET (RULE 91) ISA EP molecular graphics (i.e., 3D representations) to computational chemistry (i.e., calculations of the physical and chemical properties).
  • the present invention permits the use of molecular and computer modeling techniques to design, and select compounds, such as antibiotics or other therapeutic agents, that interact with IRS and inhibit protein synthesis.
  • the invention enables the use of atomic coordinates deposited at the RCSB Protein Data Bank with the accession number PDB ID: IFFY for the IRS/tRNA ,,e /mupirocin complex to design compounds that interact with IRS.
  • this invention enables the design of compounds that act as competitive inhibitors of IRS by binding to, all or a portion of, the active site involved in protein synthesis.
  • This invention also enables the design of compounds that act as uncompetitive inhibitors of IRS. These inhibitors may bind to, all or a portion of, the active site of IRS already bound to its tRNA 1,e and may be more potent and less non-specific than known competitive inhibitors that compete for IRS active site. Similarly, non- competitive inhibitors that bind to and inhibit IRS whether or not it is bound to another chemical entity may be designed using the atomic coordinates of IRS of this invention. Alternatively, the atomic coordinates provided by the present invention is
  • RECTIFIED SHEET (RULE 91) ISA/EP useful to design improved analogues of known IRS protein synthesis inhibitors or to design novel classes of inhibitors based on the IRS/tRNA lle /muciprocin co-complex.
  • This provides a novel route for designing IRS inhibitors with both high specificity and stability.
  • the atomic coordinates of the present invention also enables probing an IRS crystal with molecules composed of a variety of different chemical entities to determine optimal sites for interaction between candidate IRS inhibitors and IRS. For example, high resolution X-ray diffraction data collected from crystals saturated with solvent allows the determination of where each type of solvent molecule sticks.
  • the present invention enables screening computationally small molecule databases for chemical entities, agents, or compounds that can bind in whole, or in part, to IRS. In this screening, the quality of fit of such entities or compounds to the binding site may be judged either by shape complementarity or by estimated interaction energy (Meng, E. C. et al., J. Coma. Chem., 13, pp. 505-524 (1992)).
  • the design of compounds that bind to or inhibit IRS generally involves consideration of two factors.
  • the compound must be capable of physically and structurally associating with IRS.
  • Non-covalent molecular interactions important in the association of IRS with the compound include hydrogen bonding, van der Waals and hydrophobic interactions.
  • the compound must be able to assume a conformation that allows it to associate with IRS. Although certain portions of the compound will not directly participate in this association with IRS, those portions may still influence the overall conformation of the molecule. This, in turn, may have a significant impact on potency.
  • Such conformational requirements include the overall three-dimensional structure and orientation of the chemical entity or compound in relation to all or a portion of the active site of IRS, or the spacing between functional groups of a compound comprising several chemical entities that directly interact with IRS.
  • RECTIFIED SHEET (RULE 91) ISA/EP
  • the potential inhibitory or binding effect of a chemical compound on IRS may be analyzed prior to its actual synthesis and testing by the use of computer modeling techniques. If the theoretical structure of the given compound suggests insufficient interaction and association between it and IRS, synthesis and testing of the compound is obviated. However, if computer modeling indicates a strong interaction, the molecule may then be synthesized and tested for its ability to interact with IRS and inhibit protein synthesis. In this manner, synthesis of inoperative compounds may be avoided.
  • One skilled in the art may use one of several methods to screen chemical entities fragments, compounds, or agents for their ability to associate with IRS and more particularly with the individual binding pockets of the IRS active site or accessory binding site.
  • This process may begin by visual inspection of, for example, the active site on the computer screen based on the IRS coordinates deposited in the RCSB Protein Data Bank with the accession number PDB ID: IFFY. Selected chemical entities, compounds, or agents may then be positioned in a variety of orientations, or docked, within an individual binding pocket of IRS as defined supra. Docking may be accomplished using software such as Quanta and Sybyl, followed by energy minimization and molecular dynamics with standard molecular mechanics forcefields, such as CHARMM and AMBER. Specialized computer programs may also assist in the process of selecting chemical entities. These include but are not limited to:
  • GRID (Goodford, P. J., "A Computational Procedure for Determining Energetically Favorable Binding Sites on Biologically Important Macromolecules" J. Med. Chem., 28, pp. 849-857 (1985)). GRID is available from Oxford University, Oxford, UK.
  • MCSS (Miranker, A. and M. Karplus, "Functionality Maps of Binding Sites: A Multiple Copy Simultaneous Search Method.” Proteins: Structure, Function and Genetics, 11, pp. 29-34 (1991)). MCSS is available from Molecular Simulations, Burlington, Mass.
  • AUTODOCK (Goodsell, D. S. and A. J. Olsen, "Automated Docking of Substrates to Proteins by Simulated Annealing” Proteins: Structure. Function, and Genetics, 8, pp. 195-202 (1990)).
  • AUTODOCK is available from Scripps Research Institute, La Jolla, Calif.
  • DOCK (Kuntz, I. D. et al., "A Geometric Approach to Macromolecule-Ligand Interactions" J. Mol. Biol., 161, pp.269-288 (1982)). DOCK is available from
  • Assembly may proceed by visual inspection of the relationship of the fragments to each other on the three- dimensional image displayed on a computer screen in relation to the atomic coordinates of IRS. This would be followed by manual model building using software such as Quanta or Sybyl.
  • CAVEAT Bartlett, P. A. et al, "CAVEAT: A Program to Facilitate the Structure- Derived Design of Biologically Active Molecules". In “Molecular Recognition in Chemical and Biological Problems", Special Pub., Royal Chem. Soc, 78, pp. 82-196 (1989)). CAVEAT is available from the University of California, Berkeley, Calif.
  • 3D Database systems such as MACCS-3D (MDL Information Systems, San Leandro, Calif). This area is reviewed in Martin, Y. C, "3D Database Searching in Drug Design", J. Med. Chem., 35, pp. 2145-2154 (1992).
  • inhibitory or other IRS binding compounds may be designed as a whole or "de novo" using either an empty active site or optionally including some portion(s) of known inhibitors).
  • LUDI is available from Biosym Technologies, San Diego, Calif.
  • LEGEND (Nishibata, Y. and A. Itai, Tetrahedron, 47, p. 8985 (1991)). LEGEND is available from Molecular Simulations, Burlington, Mass.
  • IRS protein synthesis inhibitor must preferably demonstrate a relatively small difference in energy between its bound and free states (i.e., a small deformation energy of binding).
  • the most efficient IRS inhibitors should preferably be designed with a deformation energy of binding of not greater than about 10 kcal/mole, preferably, not greater than 7 kcal mole. IRS inhibitors may interact with the enzyme in more than one conformation that is similar
  • the deformation energy of binding is taken to be the difference between the energy of the free compound and the average energy of the conformations observed when the inhibitor binds to the IRS.
  • a compound designed or selected as binding to IRS may be further computationally optimized so that in its bound state it would preferably lack repulsive electrostatic interaction with the target enzyme.
  • Such non-complementary (e.g., electrostatic) interactions include repulsive charge-charge, dipole-dipole and charge- dipole interactions.
  • the sum of all electrostatic interactions between the inhibitor and the enzyme when the inhibitor is bound to IRS preferably make a neutral or favorable contribution to the enthalpy of binding.
  • substitutions may then be made in some of its atoms or side groups in order to improve or modify its binding properties.
  • initial substitutions are conservative, i.e., the replacement group will have approximately the same size, shape, hydrophobicity and charge as the original group. It should, of course, be understood that components known in the art to alter conformation should be avoided.
  • substituted chemical compounds may then be analyzed for efficiency of fit to IRS by the same computer methods described in detail, above.
  • the present invention further provides a method of obtaining new compounds and agents that interact with IRS from procaryotes and eucaryotes.
  • IRS from procaryotes and eucaryotes are structurally conserved.
  • the amino acid sequences of the IRS enzymes from procaryotes and eucaryotes can be aligned due to the evolutionary conservation of the identity of amino acid residues that are important for 3-D structure, the nature and shape of the binding sites for substrates (tRNA Ile , ATP and He) and the catalytic site.
  • This similarity in amino acid sequence of the homologous enzymes allows the construction of approximate models for the homologues whose crystal structures have not been solved, so-called homology modeling.
  • the present invention also provides new compounds and agents that interact with IRS and compositions comprising the new compounds or agents and carriers.
  • the compounds designed by the above methods are useful for inhibiting protein synthesis and therefore are useful as therapeutic agents to treat and prevent diseases or conditions associated with protein synthesis.
  • IRS has been classified as a group I synthetase.
  • Nagel et al. (1991, Proc. Natl. Acad. Sci. USA, 88, 8121-8125) report that all aminoacyl-tRNA synthetases within a specific group (I or II) are structurally related.
  • the region between the HIGH and KMSKS motifs (-1600 bp in length) of IRS genes of several lower eucaryotes, bacteria, and archaea Brown et al (1995, Proc. Natl. Acad. Sci. USA, 92, 2441-2445) report that the region between the HIGH and KMSKS motifs is the most conserved region both within and between
  • Nureki et al. provide the crystal structure of Thermus thermophilus IRS complexed with L-isoleucine or L-valine.
  • Nureki et al (1998) teach that the ATP binding domain of group I synthetases is constructed with a Rossmann fold.
  • Nureki et al. show that the Rossmann-fold domain of the IRS of Thermus thermophilus has a central deep catalytic cleft with two characteristic ATP-binding motifs, His 54 -Val 55 -Gly 56 -His 57 and Lys 591 -Met 592 -Ser 593 -Lys 594 on its lower level.
  • L-isoleucine/IRS complex one L-isoleucine molecule is bound at the bottom of the catalytic cleft.
  • the hydrophobic side chain of L-isoleucine is recognized by a pocket consisting of Pro 46 , Trp 518 , and T ⁇ 558 through van der Waals interactions.
  • Residues Asp 85 and Gin 554 form hydrogen bonds with NH 3 + and COO " groups respectively. According to Nureki et al. (1998), these residues are completely conserved among the 17 IRS cloned thus far.
  • IRS is structurally conserved among the different species. Accordingly, it is within the skill of the artisan to use the atomic coordinates of the S. aureus IRS/tRNA' le /muciprocin to obtain new agents that interact with IRS from other species.
  • the present invention contemplates the use of the structure of isoleucyl-tRNA synthetase complexed with tRNA and mupirocin to designing modifications to starting compounds, such as mupirocin, that will bind more tightly to the target enzyme (e.g., the IRS of S. aureus) and less tightly to the non-targeted enzyme (e.g., human IRS).
  • target enzyme e.g., the IRS of S. aureus
  • non-targeted enzyme e.g., human IRS
  • the structure of a complex between the enzyme and the starting compound can also be used to guide the modification of that compound to produce new compounds that have other desirable pharmaceutical properties, such as chemical stability, solubility or membrane permeability.
  • the structure of the enzymes from the non-targeted organism for example, the human enzyme
  • the structure of the enzymes from the non-targeted organism can be constructed by changing the structure of protein residues at the binding site for a ligand to the residues of the non-target enzyme.
  • the use of homology structure modeling to design molecules (ligands) that bind more tightly to the target enzyme than to the non-target enzyme has wide spread applicability.
  • the method outlined herein can be used to control any targeted organisms by designing ligands which inhibit the isoleucyl-tRNA synthetase of the target organisms while failing to inhibit the isoleucyl-tRNA synthetase of the non- targeted organisms to the same extent or not at all.
  • the ligands identified or prepared by the methods of the present invention can be used to control the targeted organisms
  • the ligands identified or developed using the methods of the present invention can be designed so that their administration kills the target organisms or inhibits some aspect of the target orgamsms while failing to have a similar effect on the non-targeted organism.
  • the adverse effects of the agent on the targeted orgamsms may include, but are not limited to, slowing growth rates, slowing or eliminating reproduction rates, decreasing or preventing mating, decreasing or eliminating offspring production, decreasing organism weights, decreasing or eliminating feeding, and disrupting cellular, tissue and/or organ functions.
  • Examples of targeted and non-targeted orgamsms include, but are not limited to, those provided in Table 1.
  • Table 1 Examples of the types of ligands which may be identified and/or developed by the methods of the present invention and the applicable target/non- target organisms.
  • Mupirocin inhibits many Gram-negative bacterial IRS at nM concentrations, while it binds the human enzyme at a concentration of 3 to 4 orders of magnitude higher (Hughes et al, 1980). This has been an advantage of this antibiotic because of its low toxicity.
  • the crystal structure presented here shows how mupirocin binds to a bacterial IRS and provides a detailed understanding of the binding mode and mechanism.
  • there is a very high degree of conservation (nearly invariant) surrounding the antibiotic binding cleft Wang et al, 1999a). This leads to a possible computer modeling exercise to examine discrimination mechanism in the two enzymes.
  • Sequence differences at N70/K71 of SA IRS are the only differences that are directly involved in the recognition of the antibiotic functional groups between the human and SA enzymes. This leads to re-designing of a new antibiotic, WSS-1, as described below. We also observed, not merely by coincidence, that sequence differences at the same location are present between the enzymes o S. aureus (SA) and mupirocin-resistant S. aureus (MURSA).
  • SA and MURSA IRS share a higher similar sequence homology (40% similarity) than the human and SA enzymes (38%) do.
  • the present invention provides the structure of the compound in fig. 4.
  • the present invention provides WSS-1 and compositions comprising WSS-1 and a carrier.
  • the atomic coordinates for the IRS/tRNA ,,e /WSS-l complex are deposited on July 26, 2000 at the RCSB Protein Data Bank with the accession number PDB ID: IFFY.
  • the present invention provides a method of obtaining novel compounds that interact with IRS and inhibit protein synthesis.
  • the present invention also provides compositions comprising the novel compounds.
  • the present invention contemplates a compound of formula (I):
  • R 1 is selected from the group consisting of hydrogen, and wherein n is an integer from 1 to 10;
  • R 2 is selected from the group consisting of hydrogen, — CHCH 3 — CH 2 — CH 3 , and
  • R , R and R are independently selected from hydrogen, C ⁇ -C 14 alkyl, C 2 - C 14 alkenyl, C 2 - C 14 alkynyl, C 3 - C ⁇ 4 cycloalkyl, and C 6 -C 14 aryl.
  • the present invention contemplates a compound having formula (I), wherein R 1 is
  • n is an integer from 1 to 8;
  • R 2 is and
  • R , 3 , R and R are independently selected from hydrogen and d-C 6 alkyl.
  • the present invention contemplates a compound having formula (I), wherein R 1 is
  • n 8;
  • R 2 is and
  • R 3 , R 4 and R 5 are each hydrogen.
  • the present invention provides WSS-1 shown in fig. 4. Moreover, the present invention contemplates analogs of WSS-1.
  • the various alkyl, alkenyl, and alkynyl groups may be straight or branched.
  • the alkyl, alkenyl, and alkynyl groups may be optionally substituted with halogen, alkoxy groups, or water- solubilizing groups.
  • a "water-solubilizing group” is a substituent that increases the solubiUty of a compound in aqueous solution.
  • Exemplary water-solubilizing groups include, but are not limited to, quaternary amine, sulfate, sulfonate, carboxylate, phosphate, phosphonate, polyether, polyhydroxyl, boronate, and amide groups such as --CONH 2 and CONHCH3.
  • the water solubilizing groups may also include sulfo, sulfonamido, carbonamido, sulfamoyl, carbamoyl, hydroxyl, and salts thereof.
  • RECTIFIED SHEET (RULE 91) at least one of a carbon-carbon double bond and/or at least one of a carbon-carbon triple bond.
  • the C 3 -C 22 cycloalkyl heterocycles and rings may contain more than one degree of unsaturation and may be unsubstituted or substituted.
  • the heterocycles and cycloalkyl rings may be optionally substituted with halogen, alkoxy groups, or water- solubilizing groups. These rings may be monocyclic, bicyclic, or polycyclic. In addition, these cycloalkyl rings may or may not contain one or more heteroatoms in the ring. Acceptable heteroatoms are selected from: oxygen, nitrogen, sulfur and phosphorus.
  • the C 6 -C 14 aryl ring may be monocyclic, bicyclic, or polycyclic. In addition, the aryl ring may contain one or more heteroatoms.
  • aryl includes carbocyclic aryl groups containing up to fourteen carbons, e.g., phenyl and naphthyl.
  • aryl also includes heterocyclic aryl groups such as a 5 or 6-membered heterocyclic aromatic ring.
  • heterocyclic aromatic rings may also contain other heteroatoms selected from: oxygen, nitrogen, sulphur, and phosphorous.
  • These heterocyclic aryl rings may be optionally fused to one or two phenyl rings or another 5 or 6-membered heteroaryl ring.
  • ring systems include thienyl, furyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, thiadiazolyl, oxadiazolyl, tetrazolyl, thiatriazolyl, oxatriazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, thiazinyl, oxazinyl, triazinyl, thiadiazinyl, oxadiazinyl, dithiazinyl, dioxazinyl, oxathiazinyl, tetrazinyl, thiatriazinyl, oxatriazinyl, dithiadiazinyl, imidazolinyl, dihydropyrimidyl, tetrahydropyr
  • aryl groups may be substituted or unsubstituted as discussed above for the alkyl, alkenyl, and alkynyl groups.
  • aryl includes arylene groups.
  • arylene defines a divalent carbocyclic aryl hydrocarbon moiety containing up to fourteen carbons, e.g., o-, m- and p-phenylene, and those substituted with one or two groups selected from d-Q-alkyl, d-C 4 -alkoxy or halogen.
  • the present invention contemplates compositions comprising WSS-1 or its analogs and at least one carrier.
  • the present invention is based in part on the finding that the synthetic active site of three editing tRNA synthetases comprises the HIGH, KMSK, and WCISR motifs of the dinucleotide Rossmann fold domain and the CWRC motif of the editing domain.
  • the present invention is also based on the discovery that the hydrolytic active site comprises the TTXPXT and GTGX1 ID motifs of the editing domain. Additionally, the present invention is based on the comparison of the tRNA-free T. Thermophlius isoleucyl-tRNA synthetase in a resting state, tRNA-bound E.
  • the present invention is based on the finding that an RNA binding domain at the anticodon recognition site ensures the tRNA releasing via the hydrolytic mode.
  • IRS comprises 7 domains (Fig. 7): amino terminal, dinucleotide Rossmann fold, connective peptide- 1 (CPl or editing domain), connective peptide-2 (CP2), helical, carboxyl terminal junction, and Zn binding domains.
  • Rossmann fold domain in this structure is broken into three parts (Fig. 7) with two insertions of CPl and CP2 and has a different topology than the one in the glutaminyl tRNA synthetase (QRS) structure (Rould et al, 1989).
  • QRS glutaminyl tRNA synthetase
  • IRS there is an extra parallel strand connecting a pair of ⁇ -helices that bind the tRNA acceptor stem (Fig. 7b) at the one (QRS) structure (Rould et al, 1989).
  • IRS there is an extra parallel strand connecting a pair of ⁇ -helices that bind the tRNA acceptor stem (Fig. 7b) at the one side of the ⁇ -sheet, and on the other side of the ⁇ -sheet, a strand runs in an opposite direction as in QRS.
  • the anticodon recognition site is made of four domains: amino terminal, helical, carboxyl terminal junction, and Zn binding domains (Fig. 7), three of which share novel motifs with two functionally related and an unrelated proteins.
  • the folding motif of the editing domain is unique to this synthetase (Nureki et al, 1997) and does not share similarity with any known structure in the DALI data base (Holm and sander, 1998).
  • IRS binds tRNA using four synthetase parts (Fig. 7, 9): the putative helix- turn-strand-turn (H-T-S-H) motif that directs the orientation of the tRNA at the inner corner of the L-shaped tRNA (Perona et al, 1991), two pairs of helices, and surprisingly the KMSK loop.
  • One pair of parallel helices binds the anticodon stem using 14 side chains and two bound metal ions (Wang et al, 1999a), and the other pair of antiparallel bind the acceptor stem (Fig.8).
  • the binding of the tRNA to the KMSKS loop directly controls the switching of IRS from a resting to synthetic and to hydrolytic modes, as described below.
  • Synthetic Active Site of Class I tRNA Synthetases Glutaminyl-tRNA synthetase (QRS) in the complex with tRNA and adenylate analogous inhibitor, QSI, provides a direct view of the synthetic complex of all class I tRNA synthetases (Rould et al, 1989), including three editing tRNA synthetases.
  • the synthetic active site is made of the HIGH, WCISR, and KMSK motifs of the dinucleotide Rossmann fold domain and the LX2R motif from the "CPl " domain.
  • RECTIFIED SHEET (RULE 91) ISA/EP motifs of the dinucleotide Rossmann fold domain as previously observed (Rould et al, 1989) and the CWRC motif of the editing domain as described below.
  • the hydrolytic active site (Fig. 7) is made of the TTXPXT and GTGX1 ID motifs of the editing domain (Nureki et al, 1998).
  • the editing domain is absent in the other two members of class la non-editing tRNA synthetases, methionyl- and cysteinyl-tRNA synthetases or MRS and CRS (Fig. 7C).
  • a switching from a synthetic to hydrolytic modes in IRS involves three of the four motifs: KMSK, WCISR, and CWRC, as described below. We examine these three switching in three distinct states of IRS, a resting, synthetic, and hydrolytic, using QRS as a reference point. 4. Three States of the KMSK Motif
  • the KMSK motif in a loop in IRS binds to the tRNA acceptor stem and is directly coupled with the H-T-S-H motif by 5 hydrogen bonds (Wang et al, 1999a).
  • a highly conserved carboxylate (D630) at the turn of the H-T-S-H motif makes two hydrogen bonds with two Gua69 ribose hydroxyls and one hydrogen bond to the KMSK backbone at position 587, which is at the very beginning of the K(595)MSK loop. This allows the KMSK loop backbone atoms at positions 593 and 595 to bind both the tRNA Gua68 ribose hydroxyl and Gua69 phosphate (Wang et al, 1999a).
  • the KMSK loop conformation in the tRNA-bound Sau IRS structure is induced by the binding of the tRNA.
  • the loop In the tRNA-free (and adenylate-free) Tth IRS structure in a hydrolytic mode, the loop has very large temperature B-factors (Nureki et al, 1997), and the loop cannot make the same interactions as in the complex structure with the imported tRNA after overlaying the two Rossmann fold domains, due to a difference of over 3.6 A (at K594 in Tth IRS) between the two structures. This is a difference in the KMSK loop between the two states of IRS, the hydrolytic and the resting.
  • the difference extends to the entire tRNA binding surface of the synthetase: the H-T- S-T motif, the two pairs of helices (one pair at the acceptor and the other pair at the anticodon binding sites), and of course the KMSK loop itself.
  • the binding site for example, three remaining helices in the helical domain superimpose well in the two states of IRS, indicating a deformation motion in the domain.
  • the binding of tRNA induces a relative motion of the dinucleotide Rossmann fold domain with the rest of the structure.
  • the difference in the KMSK loop becomes even smaller (8.3 A) between the two structures of E. coli QRS in the synthetic mode and Tth apo IRS in the resting mode using the supe ⁇ osition of the two Rossmann fold domains.
  • the difference is 14.6 A between these two structures of Tth IRS and E. coli QRS, when Tth apo IRS is imported to the Sau IRS reference frame by the supe ⁇ osition of the two Rossmann fold domains, and QRS is imported to the same reference frame by the supe ⁇ osition of the two tRNAs.
  • the KMSK Loop Controls the Release of the Synthetic Products
  • the KMSK loop controls the accessibility of amino adenylates in class I tRNA synthetases. When an amino adenylate is absent, the loop is often disordered or has large temperature B-factors (Monteilhet et al, 1984, Brick et al, 1988, Nureki et al, 1998). In the presence of amino adenylate, or its analogous inhibitor, or ATP, the second lysine (K598 in Sau IRS and K270 in E.
  • coli QRS in the loop binds both ⁇ and ⁇ -phosphate of ATP or its analogous position of QSI in the QRS complex structure (Rould et al, 1989, Rath et al, 1998).
  • QSI an amino adenylate with a nonhydrolyzable glutamine- ATP linkage
  • similarly designed inhibitors bind tightly to non-editing class I tRNA synthetases is that there is an additional domain on top of the KMSKS loop (Fig. 9E) to limit the loop motion and to prevent the activated amino acids from unnecessarily diffusing out.
  • the KMSK switching involves metal ion mediated tRNA-synthetase recognitions (Wang et al, 1999a) at the inside corner of the L-shaped tRNA near the D-loop (Fig. 7, 9).
  • D626 conserved carboxylate
  • R632 a partially conserved, positively charged residue makes two hydrogen bonds with phosphate backbone of both Uril3 and Cytl3 (Wang et al, 1999a).
  • the second helix in the motif provides an additional 5 side chains for formation of 6 hydrogen bonds with the tRNA.
  • an additional long ⁇ -helix provides 8 side chains for binding to the tRNA lle (LAU) isoacceptor and 7 for the tRNA lle (GAU) isoacceptor, directly mediated by two bound metal ions (Wang et al. , 1999a).
  • LAU tRNA lle
  • GAU tRNA lle
  • tRNA 1,e and tRNA fmet superimpose well with each other at both the T-loop and D-loops and that both tRNAs belong to a subfamily of ⁇ 3 ⁇ l, according to number of nucleotides in positions ⁇ and ⁇ (Kim, et al, 1974).
  • tRNA gln and tRNA phe superimpose well, and both belong to a subfamily of ⁇ 2.
  • tRNA phe Since both tRNA val and tRNA phe belong to the ⁇ 2 ⁇ l subfamily, we decided to use tRNA phe as a model for tRNA val to examine the consequence of the D-loop transplantation. At a minimum, the tRNA would lose three hydrogen bonds (Fig. 9D), two with R632 (Uril2-O2P and cytl3-01P) and one with the backbone amine of N235 (Uril2-O2').
  • the WCIRS and CWRC motifs in editing tRNA synthetases provide three positively charged residues and two hydrophobic residues to stabilize the 3' tRNA end hai ⁇ in structure when it is present in the hypothetical IRS synthetic mode on the basis of modeling (Silvian et al, 1999). Differences (3-5 A, see below) in these motifs between the hypothetical synthetic structure and the resting Tth apo IRS is much smaller than those (16.3 A) between the structures of resting apo Tth IRS and hydrolytic Sau IRS.
  • R457 would have the exactly same orientation and binding function as K194 in QRS (Rath et al, 1998). This requires a reorientation of the CPl domain and breaking inter-domain hydrogen bonds involving this residue.
  • the CWRC motif of the IRS editing domain conserved among all three editing tRNA synthetases, is equivalent to the RX2L motif in QRS.
  • the equivalence is apparent when apo Tth IRS in a resting mode is imported to the Sau JJR.S reference frame by the supe ⁇ osition of the two Rossmann fold domains (Fig.
  • the CPl domain contribute three residues, R391, W390, and L195 for the same function as R133 and L136 in QRS.
  • a distance between R390 and LI 95 C ⁇ in Tth IRS is the same as R133 and LI 36 in QRS, 9.7 A; and the orientation of two side chains is also similar. If the CPl in the hypothetic synthetic mode is displaced upwards as indicated in the figure (Fig. 10A) by 5.0 A, R391 and L195 would have an identical geometry as
  • RECTIFIED SHEET (RULE 91) ISA/EP the displacement should actually be less than 5.0 A.
  • R391 and L195 in Tth IRS resemble R133 and LI 36 in QRS only in the three-dimensional structure but not in the primary sequence. This is an example of structural element swapping (see below).
  • the residues WR of the CWRC motif are strictly conserved among all known editing tRNA synthetases in the public data base, but not among non-editing tRNA synthetases (Fig. 7C). In LRS, the CWRC motif is transposed from the ending of the editing domain to its beginning (Fig. 7C).
  • the CWRC motif in the resting Tth apo IRS state is about 3-5 A closer to the synthetic active site than it should be in the hypothetical synthetic state, derived from the QRS structure. This resting conformation state is maintained by, and directly results from, 7 conserved inter- domain hydrogen bonds immediately underneath it (Fig. 10C). Inter-domain hydrogen bonds include the two conserved, positively charged residues of WCISR motif (R448 and R450 in Tth IRS, and R455 and R457 in Sau IRS).
  • the CWRC motif in the hydrolytic Sau IRS state is displaced about 16.3 A (at R391 C ⁇ ) away from it in the resting state (Fig. 10E) .
  • the tRNA binds IRS in a deep cleft made of domains not present in QRS. This includes four anticodon binding domains: helical, C-terminal junction, Zn- binding domain, and amino terminal domains.
  • the tRNA can bind to, and be released from, the synthetase in the three indicated directions (Fig. 1 IC): left horizontal, up vertical, and out towards the viewer.
  • Fig. 1 IC left horizontal, up vertical, and out towards the viewer.
  • a hypothetical synthetic complex is constructed on Sau IRS with its CPl domain oriented according to Tth apo IRS, and tRNA from QRS complex (Fig. 11 A).
  • the first step that allows the tRNA to be released from IRS is that the editing domain has to be pushed out of the way to force the tRNA to go through the
  • IRS RECTIFIED SHEET (RULE 91) ISA/EP After releasing the tRNA, IRS returns to a resting state as in Tth IRS with 7 inter- domain hydrogen bonds. In this exiting path, all charged tRNA ,,e molecules are checked for errors.
  • tRNA-induced editing function of IRS is highly analogous to that in DNA polymerases (Silvian et al, 1999), with the exception of a large motion of the editing domain (Fig. 12).
  • the two active sites located in two isolated clefts in two domains are separated by 34 A (Fig. 12E-G).
  • a large swiveling motion of the editing domain which takes place before the releasing of the tRNA, allows the two active sites to be internally aligned on a contiguous surface (Fig. 12G). This facilitates the shuttling of either noncognate valine-adenylate or mischarged valine- tRNA lle to the hydrolytic active site for subsequent hydrolysis.
  • tRNA mini-helices may bind to IRS at much lower affinity and occasionally be charged (Nordin and Schimmel, 1999), but they are neither checked by the anticodon recognition mechanism nor by hydrolytic releasing pathway.
  • IRS Anticodon Binding Domains with Other Proteins
  • All IRS large domains are unique and in a class by themselves with the exception of the dinucleotide Rossmann fold domain, which is shared by all class I tRNA synthetases and many other proteins (Fig. 7).
  • the editing domain does not share any structural homology with known structures in the DALI data base (Nureki et al, 1998). This is a novel ⁇ -barrel like structure.
  • the helical domain is found only in a non-editing tRNA synthetase of known structure, namely tRNA met synthetase, MRS (Brunie et al, 1990); however, this is the first time that we have observed a domain employs novel metal ion-mediated protein-nucleic acid interaction to bind tRNA (Wang et al, 1999a).
  • the C-terminal junction and Zn binding domains share the folding motif with one functionally related and one unrelated proteins, as described below.
  • the C-terminal junction domain shares a folding similarity with a subunit of protein synthesis apparatus, ribosomal L22 (Unge et al, 1998), in an ⁇ -helix and two middle strands of the four-stranded ⁇ -sheet (Fig. 13 A).
  • the two outer strands of the four strands were not identified as homologous structures by the DALI alignment procedure (Holm and Sander, 1998), because they are unrelated in the primary sequence. In these two structures, all four strands appear to align, or at least the two outer strands occupy the same locations (Fig. 13 A).
  • the top strand (Fig.
  • the Zn binding domain shares a folding similarity with a membrane- targeting, Zn-binding motif, FYVE (Misra and Hurley, 1999), which is dependent on phosphatidylinositol 3-phosphate (PI3P), a functionally unrelated motif (Fig. 13B).
  • FYVE phosphatidylinositol 3-phosphate
  • Fig. 13B a functionally unrelated motif
  • the second, the two functionally unrelated proteins share an architecture in the binding sites for two unrelated substrates.
  • W890 of the Zn binding domain and L7 of the amino terminal domain form the pocket for the binding of Gua34 (Wang et al, 1999a); in the membrane-target motif, a similar location between the two Zn binding sites is predicted to bind PI3P (Misra and Hurley, 1999).
  • PI3P PI3P
  • Example 1 The preparation of tRNA' le and IRS
  • T7 RNA polymerase The gene for the major isoacceptor of tRNA lle (GAU) from E. coli was cloned behind a T7 RNA polymerase promoter with a BstNI site at its 3 1 terminus to produce run-off transcripts (Rice, L, Smerdon, S., and Steitz, T.A, unpublished results). T7 RNA polymerase was overexpressed and purified according to D. Jeruzalmi (PhD thesis, 1995, Yale University). Production of plasmid encoding the E.
  • coli sequence tRNA lle (GAU) was scaled up according to the Biofeedback's protocol and was digested, transcribed, purified, and folded as the tRNA gln protocol (Silvian, L.F., PhD thesis, 1997, Yale University). IRS from S. aureus was overexpressed and purified according to Chalker et al, (1994) and dialyzed into storage buffer containing 20 mM Tris HC1 pH 8.0, ImM DTT, 5 mM MgCl 2 , 50% glycerol, and kept at a -70°C freezer. The overexpression clone, and purified IRS protein sample used in the initial stage of the present invention were kindly provided Dr. S.
  • tRNA transcript 50 mM KC1, 5mM MgCl 2 , 2mM ⁇ -mercaptoethanol, ImM ZnCl 2 and concentrated to 20 mg/ml in a centricon-15 (Amicon).
  • the tRNA transcript was folded by dissolving a lyophilized pellet in 10 mM Na Cacodylate pH 6.0, 5 mM MgCl 2 at a concentration of 5 mg/ml, heating at 60°C for 5 minutes and then slow-cooling to 25°C for an hour. The tRNA was then lyophilized and dissolved to a concentration of 20 mg/ml with 40 mM Na Cacodylate pH 6.0 and 20 mM MgCl 2 .
  • the complex of 50 uM IRS, 50 uM tRNA and ImM mupirocin were mixed with the well solution at a volume ratio of 3 ul well: lul complex.
  • the well solution contained 12% PEG6K, 0.3M KC1, lOOmM Na Cacodylate pH 6.3, lOOmM MgSO , 2mM ZnCl 2 , and 0.1% ⁇ -octyl glutopyranoside.
  • the drops were streak-seeded without prior equilibration and then equilibrated at 20°C by the hanging-drop method.
  • Crystals were frozen by replacing the mother- liquor with a cryoprotectant containing the well solution with the addition of PEG 6K to a final concentration of 20%(w/v) and ethylene glycol to a final concentration of 15%(v/v) and then flashed-freezing in liquid propane.
  • the mother liquor is the equilibrated crystal drop solution containing the well solution (the same chemicals and concentration) plus mupirocin and very low concentrations of IRS and tRNA.
  • Example 3 Structure Determination
  • the 18 selenium sites of selenomethionine-inco ⁇ orated IRS per asymmetric unit were located using the program SOLVE (Terwilliger, 1994) on MAD data that had been locally scaled using MADPRB (Friedman, et al, 1994). Refinement in CNS (Brunger et al, 1998) with a maximum likelihood Henderickson Lattman (MLHL) target yielded an overall R f re e values of 28.1% for reflections
  • Derivatives were phased in MLphare using CCP4 (CCP4, 1994) by a novel method called permuting the Native Derivative (Wang, J., unpublished results).
  • CCP4 CCP4
  • Phase improvement was measured by the objective criterion of monitoring the height of a difference Fourier peak of an independent derivative for which there was a clear different Patterson peak. Using the selemum derived phases, additional sites in other derivatives were identified.
  • the MAD and MIR phase sets from all derivatives were combined using SigmaA (CCP4, 1994) weighting and the resultant map modified in SOLOMON (Abrahams and Leslie, 1996).
  • the heavy atom parameters were independently refined using density modified external phases (Rould et al., ⁇ 992) and all phase sets were combined again.
  • the course of the backbone of the entire protein was traced using experimental maps with the exception of a region between residues 205-390 in the editing (CPl) domain and the last nucleotides of the tRNA.
  • Human isoleucyl-tRNA synthetase has A65 and G66, corresponding to N70 and K71 of IRS in SA.
  • the modeling of the human enzyme was done by the removal of the respective side chains at the equivalent residues.
  • MURSA has G55 and R56 as the same location.
  • the mutation of N to G was done by the removal of the asparagine
  • the re-designed antibiotic, WSS-1 was a fusion product of an asparagine side chain to the existing antibiotic, mupirocin, through a methylene linker at 07 while replacing O7 with N7.
  • the location of the side chain moiety would allow a cyclization of C ⁇ 2 to both C ⁇ and C16, to the latter of which it is attached in a chair conformation of the 6-membered ring. This ensures the side chain equivalent component will sit above G55 in MURSA and will be rejected by A65 in human.
  • An introduction of a hydroxyl at C ⁇ l and a reduction of the unsaturated bonds will allow its interaction with R56 in MURSA, which is not present in the human enzyme.
  • valyl-tRNA synthetase from Bacillus stearothermophlius has considerable sequence homology with the isoleucyl-tRNA synthetase from Escherichia coli. Biochemsitry 26, 2480- 2486.
  • Crystallography & NMR system A new software suite for macromolecular structure determination. Acta Crystallogr. D. Biol. Crystallogr. 54, 905-921.
  • CCP4 Collaborative computational project No. 4. (1994). Acta Cryst. D50, 760.
  • Evidence for the double-sieve editing mechanism in protein synthesis Steric exclusion of isoleucine by valyl-tRNA synthetases. Biochemistry 18, 2627-2631 Fersht, A.R., and Dingwall, C. (1979b).
  • Mechanism of aminoacylation of tRNA Proof of the aminoacyl adenylate pathway for the isoleucyl- and tyrosyl-tRNA synthetases from Escherichia coli K12. Biochemistry 15, 818-823.
  • Nancomycin-resistant Staphylococcus aureus an emerging public health threat. Cleve. Clin. J. Med. 64, 527-532.
  • Pseudomonic acid an antibiotic produced by Pseudomonas fluorescens. Nature 234, 416-417. Fersht, A.R., Knill-Jones, J.W., Bedouelle, H., and Winter, G. (1988). Reconstruction by site-directed mutagenesis of the transition state for the activation of tyrosine by the tyrosyl-tRNA synthetase: a mobile loop envelopes the transition state in an induced- fit mechanism. Biochemistry 27, 1581-1587.
  • Lysine 335 part of the KMSKS signature sequence, plays a crucial role in the amino acid activation catalysed by the methionyl-tRNA synthetase from Echerichia Coli. J. Mol. Biol. 217, 465-475.
  • RNA determinants for translation editing Mischarging a minihelix substrate by a tRNA synthetase. J. Biol. Chem. 214, 6835- 6838.
  • Pope, A.J., McVey, M., Fantom, K., and Moore, K.J. Effects of substrate and inhibitor binding on proteolysis of isoleucyl-tRNA synthetase from Staphylococcus aureus. J. Biol. Chem. 273, 31702-31706. Pope, A.J., Moore, K.J., McVey, M., Mensah, L., Benson, N., Osbourne, N., Broom, N., Brown, M.J., and O'Hanlon, P. (1998).Characterization of isoleucyl-tRNA synthetase from Staphylococcus aureus. II. Mechanism of inhibition by reaction intermediate and pseudomonic acid analogues studied using transient and steady-state kinetics. J. Biol. Chem. 273, 31691-31701.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne les coordonnées atomiques obtenues par cristallographie par rayons X à haute résolution du complexe de co-cristal comprenant de la mupirocine et son enzyme cible, la synthétase ARNt-isoleucyle issue du Staphylococcus aureus, et le ARNtile parent issu de Escherichia coli. La présente invention concerne également des procédés d'utilisation des cordonnées atomiques pour identifier et concevoir de nouveaux médicaments qui modulent la synthèse des protéines ainsi que les agents eux-mêmes.
PCT/US2000/020735 1999-07-29 2000-07-31 UTILISATION DE LA STRUCTURE CRISTALLINE DE LA SYNTHETASE ARNt-ISOLEUCYLE DU STAPHYLOCOCCUS AUREUS DANS LA CONCEPTION D'ANTIBIOTIQUES WO2001009154A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU63915/00A AU6391500A (en) 1999-07-29 2000-07-31 Use of the crystal structure of staphylococcus aureus isoleucyl-trna synthetase in antibiotic design
CA002380335A CA2380335A1 (fr) 1999-07-29 2000-07-31 Utilisation de la structure cristalline de la synthetase arnt-isoleucyle du staphylococcus aureus dans la conception d'antibiotiques
EP00950881A EP1200564A2 (fr) 1999-07-29 2000-07-31 UTILISATION DE LA STRUCTURE CRISTALLINE DE LA SYNTHETASE ARNt-ISOLEUCYLE DU STAPHYLOCOCCUS AUREUS DANS LA CONCEPTION D'ANTIBIOTIQUES

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14617699P 1999-07-29 1999-07-29
US60/146,176 1999-07-29

Publications (2)

Publication Number Publication Date
WO2001009154A2 true WO2001009154A2 (fr) 2001-02-08
WO2001009154A3 WO2001009154A3 (fr) 2001-07-26

Family

ID=22516158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020735 WO2001009154A2 (fr) 1999-07-29 2000-07-31 UTILISATION DE LA STRUCTURE CRISTALLINE DE LA SYNTHETASE ARNt-ISOLEUCYLE DU STAPHYLOCOCCUS AUREUS DANS LA CONCEPTION D'ANTIBIOTIQUES

Country Status (5)

Country Link
US (1) US6631329B1 (fr)
EP (1) EP1200564A2 (fr)
AU (1) AU6391500A (fr)
CA (1) CA2380335A1 (fr)
WO (1) WO2001009154A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013167A3 (fr) * 2002-08-01 2004-05-06 Affinium Pharm Inc Nouveaux polypeptides purifies issus d'enterococcus faecalis
EP2066789A4 (fr) * 2006-09-29 2009-12-30 Anacor Pharmaceuticals Inc Structure cristalline d'une arnt synthetase

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070118296A1 (en) * 2003-11-07 2007-05-24 Dna Software Inc. System and methods for three dimensional molecular structural analysis
CN112933243B (zh) * 2021-01-25 2023-06-27 中山大学 一种异亮氨酰tRNA合成酶与雷弗霉素A的复合物晶体及其制备方法和应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
L F SILVIAN ET AL.: "Insights into editing from an Ile-t RNAS synthetase structure with tRNA and mupirocin" SCIENCE., vol. 285, 13 August 1999 (1999-08-13), pages 1074-1077, XP002160175 AAAS. LANCASTER, PA., US cited in the application *
O NUREKI ET AL.: "Enzyme structure with two catalytic sites for double-sieve selection of substrates" SCIENCE., vol. 280, 24 April 1998 (1998-04-24), pages 578-582, XP002160173 AAAS. LANCASTER, PA., US cited in the application *
S P HALE ET AL.: "Discrete determinants in transfer RNA for editing and aminoacylation" SCIENCE., vol. 276, 23 May 1997 (1997-05-23), pages 1250-1252, XP002160174 AAAS. LANCASTER, PA., US cited in the application *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004013167A3 (fr) * 2002-08-01 2004-05-06 Affinium Pharm Inc Nouveaux polypeptides purifies issus d'enterococcus faecalis
EP2066789A4 (fr) * 2006-09-29 2009-12-30 Anacor Pharmaceuticals Inc Structure cristalline d'une arnt synthetase

Also Published As

Publication number Publication date
CA2380335A1 (fr) 2001-02-08
WO2001009154A3 (fr) 2001-07-26
EP1200564A2 (fr) 2002-05-02
AU6391500A (en) 2001-02-19
US6631329B1 (en) 2003-10-07

Similar Documents

Publication Publication Date Title
Mahanta et al. Biosynthesis and chemical applications of thioamides
Perona et al. Synthetic and editing mechanisms of aminoacyl-tRNA synthetases
Zoll et al. Ligand-binding properties and conformational dynamics of autolysin repeat domains in staphylococcal cell wall recognition
Du et al. Crystal structure and enantiomer selection by D-alanyl carrier protein ligase DltA from Bacillus cereus
Han et al. Streptomyces wadayamensis MppP is a pyridoxal 5′-phosphate-dependent l-arginine α-deaminase, γ-hydroxylase in the enduracididine biosynthetic pathway
Anstrom et al. Structure of the Escherichia coli malate synthase G: pyruvate: acetyl‐coenzyme A abortive ternary complex at 1.95 Å resolution
Im et al. The crystal structure of alanine racemase from Streptococcus pneumoniae, a target for structure-based drug design
US10723770B2 (en) Crystal structure of the large ribosomal subunit from S. aureus
Zhang et al. Structural and functional studies of fatty acyl adenylate ligases from E. coli and L. pneumophila
Patteson et al. Structure and function of a dehydrating condensation domain in nonribosomal peptide biosynthesis
NO342699B1 (no) Et bakterielt ATP-syntasebindingsdomene.
Stanisic et al. Engineered nonribosomal peptide synthetase shows opposite amino acid loading and condensation specificity
Ravulapalli et al. Characterization of vis toxin, a novel ADP-ribosyltransferase from Vibrio splendidus
Behrens et al. Homodimer architecture of QTRT2, the noncatalytic subunit of the eukaryotic tRNA-guanine transglycosylase
US7133783B2 (en) X-ray crystal structures of functional ribosome complexes containing transfer RNA and model messenger RNAs and methods of use
Wyllie et al. Biosynthesis of uridine diphosphate N‐Acetylglucosamine: An underexploited pathway in the search for novel antibiotics?
US6631329B1 (en) Use of the crystal structure of Staphylococcus aureus isoleucyl-tRNA synthetase in antibiotic design
WO2002068933A3 (fr) Conception de petites molecules efficaces contre des mutants resistants aux medicaments au moyen d'evolution dirigee
Gnann et al. Studies of a siderophore-producing cyclization domain: A refined proposal of substrate binding
Pang Structural Characterization of Aminoacyl-tRNA Synthetase Inhibitors as Antibiotics and Tools for Enzyme Mechanistic Studies
Puvar Investigations into Noncanonical Ubiquitination
Sternicki Biotin protein ligase as a novel antifungal drug target
Zandi EVOLUTION, FUNCTION, AND INHIBITION OF L, D TRANSPEPTIDASE ENZYMES OF MYCOBACTERIA
Asiri Development of novel antibacterial agents through the design and synthesis of Aminoacyl tRNA Synthetase (AaRS) inhibitors
Zhou et al. Bifunctional NadC Homologue PyrZ Catalyzes Nicotinic Acid Formation in Pyridomycin Biosynthesis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2380335

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000950881

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000950881

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000950881

Country of ref document: EP